RESVERLOGIX EXPANDS INTELLECTUAL PROPERTY PORTFOLIO TO INCLUDE DRUG ELUTING MEDICAL DEVICES

Resverlogix Corp. (TSX:RVX) announced today that on behalf of its wholly owned subsidiary, RVX Therapeutics, it has filed a patent application covering a unique and expanded application of its cardiovascular technology. RVX Therapeutics has discovered pharmaceutical compounds which have the potential to be used with medical devices such as drug-eluting stents.

CCNMatthews (http://www.ccnmatthews.com/news/releases/show.jsp?action=showRelease&actionFor=551069)